myeloid progenitor cells
Hematopoietic stem cells (HSCs) are the stem cells that give rise to other blood cells. This process is called haematopoiesis. In vertebrates, the first definitive HSCs arise from the ventral endothelial wall of the embryonic aorta within the (midgestational) aorta-gonad-mesonephros region, through a process known as endothelial-to-hematopoietic transition. In adults, haematopoiesis occurs in the red bone marrow, in the core of most bones. The red bone marrow is derived from the layer of the embryo called the mesoderm. Recent study marks the first global discovery of hematopoietic stem cell (HSC) niches within invertebrate skeletons—overturning the long-held belief that skeletal hematopoiesis is unique to vertebrates, offering a novel evolutionary perspective on stem cell biology. — Wikipedia
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Earliest trial started Apr 1, 2009 (NCT00891137)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Hematologic Neoplasms · Phase 1
- Hodgkin Disease · Phase 1
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 1
- Neoplasms, Plasma Cell · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Primary Myelofibrosis · Phase 1
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHematopoietic stem cell ↗
Also known as
- myeloid progenitor cell
- myeloid progenitor cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02129582 | Phase 1 | Jun 6, 2014 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT01297543 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2011 | Cellerant Therapeutics, Department of Health and Human Services |
| NCT00891137 | Phase 1 | Apr 1, 2009 | Cellerant Therapeutics, Department of Health and Human Services, University of Minnesota |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellerant Therapeutics | For profit | 2 | 2 | 2 | 2009 |
| Department of Health and Human Services | Government | 2 | 0 | 2 | 2009 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2014 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2009 |